First human test of experimental brain injection for rare neurological disease

NCT ID NCT04539041

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety of an experimental drug called NIO752 in people with progressive supranuclear palsy (PSP), a rare and serious brain disorder. Fifty-nine participants received either the drug or a placebo via spinal injections over several months. The main goal was to check for side effects and see how the drug moves through the body, not to treat the disease itself.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Novartis Investigative Site

Montreal, Quebec, H2X 1R9, Canada
Novartis Investigative Site

Montreal, Quebec, H3A 2B4, Canada
Novartis Investigative Site

Bonn, North Rhine-Westphalia, 53127, Germany
Novartis Investigative Site

Düsseldorf, 40225, Germany
Novartis Investigative Site

Hanover, 30625, Germany
Novartis Investigative Site

München, 81377, Germany
Novartis Investigative Site

Tübingen, 72076, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Southampton, SO16 6YD, United Kingdom
University of California San Diego

La Jolla, California, 92037, United States
Vanderbilt University Medical CenterX

Nashville, Tennessee, 37221, United States

Conditions

Explore the condition pages connected to this study.

PROGRESSIVE SUPRANUCLEAR PALSY (PSP)